(Press-News.org) Belgrade, Serbia – 17 May 2025. A pharmaceutically produced cannabidiol formulation had a good overall safety profile, including cardiac safety, according to research presented today at Heart Failure 2025,1 a scientific congress of the European Society of Cardiology (ESC).
Currently, there are limited treatment options for inflammatory conditions of the heart, such as myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the membrane surrounding the heart). Cannabidiol – which lacks the psychotropic effects of cannabis – has been shown to inhibit activation of the inflammasome pathway,2 an intracellular process known to be involved in the development and progression of myocarditis, pericarditis and heart failure.
Explaining the rationale for the current trial, Co-Principal Investigator, Dr. Leslie Cooper from the Mayo Clinic, Jacksonville, Florida, USA, said: “We knew that patients with cardiovascular disease (CVD) or CVD risk factors who were hospitalised for COVID-19 infection may be at high risk of cardiac inflammation. We conducted a placebo-controlled trial of an oral pharmaceutically manufactured (GMP) cannabidiol formulation to assess its efficacy and safety. The pandemic ended before we had recruited sufficient participants to analyse whether GMP-cannabidiol had a positive effect on the primary efficacy endpoint but we thought that the lack of safety signals was important data to share.”
This prospective trial included adult patients with a prior history of CVD and/or at least one major risk factor for CVD who had been hospitalised for non-critical COVID-19 infection. Participants were randomised to either GMP-cannabidiol titrated up to 7.5 mg/kg twice daily (or maximum tolerated dose) or placebo. The primary safety endpoint was the number of serious adverse events (SAEs) and adverse events (AEs) during the 60 days following randomisation.
The trial was terminated early due to a lack of eligible patients with COVID-19 to support full recruitment. The recruited safety population included 89 patients (mean age of 61 years; 43% female): 45 patients received GMP-cannabidiol and 44 received placebo.
Overall safety was similar between the groups. The frequency of investigator-assessed treatment-related AEs was 24.4% with GMP-cannabidiol and 22.7% with placebo. The frequency of SAEs was 11.1% with GMP-cannabidiol and 9.1% with placebo. There were 0 deaths in the GMP-cannabidiol group and 2 deaths in the placebo group, both due to respiratory failure.
There were no significant differences between groups in the most common AEs of gastrointestinal disorders (GMP-cannabidiol: 22.2%; placebo: 20.5%); nervous system disorders (GMP-cannabidiol: 17.8%, placebo: 18.2%); and respiratory, thoracic and mediastinal disorders (GMP-cannabidiol: 11.1%, placebo: 9.1%).
Of note, the cardiovascular safety profile of GMP-cannabidiol appeared similar to that of placebo. Cardiac disorders were reported in 4 patients (9%) in both the GMP-cannabidiol group and the placebo group. One patient (2%) in the GMP-cannabidiol group developed mild QTc prolongation detected by electrocardiogram (ECG). However, overall, changes in ECG measurements were minimal, with similar mean QTc values from baseline to day 28 in the GMP-cannabidiol group (425 msec and 418 msec, respectively) and in the placebo group (418 msec and 419 msec, respectively).
Summarising the findings, Dr. Cooper said: “GMP-cannabidiol was well tolerated overall and most importantly, the rate of cardiac side effects was low and similar compared with placebo. These safety data are encouraging as two larger trials assessing efficacy and safety are underway with GMP-cannabidiol. The phase II ARCHER trial3 in patients with acute myocarditis is expected to report later in 2025, while results from the phase III MAVERIC trial4 in patients with recurrent pericarditis are expected in 2026.”
ENDS
ESC Press Office
Tel: +33 6 61 40 18 84
Email: press@escardio.org
Follow us on X @ESCardioNews
Funding: The trial was funded by Cardiol Therapeutics Inc.
Disclosures: Dr. Cooper serves as a consultant to Cardiol Therapeutics Inc.
References and notes:
1‘Cardiac safety of pharmaceutically manufactured cannabidiol in patients at increased cardiovascular risk’ will be presented during ePosters in myocardial disease (1) on 17 May at 10:46 CET on ePosters screen 13 in the Research Gateway.
2Martinez Naya N, Kelly J, Corna G, et al. Molecular and cellular mechanisms of action of cannabidiol. Molecules. 2023;28:5980.
3McNamara D, Cooper LT, Arbel A, et al. Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: Rationale & design of the ARCHER trial. ESC Heart Fail. 2024;11:3416–3424. NCT05180240.
4NCT06708299.
About the European Society of Cardiology
The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.
About Heart Failure 2025
Heart Failure is the annual congress of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). #HeartFailure2025
About the Heart Failure Association
The Heart Failure Association (HFA) is a branch of the European Society of Cardiology (ESC). Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Information for journalists about registration for Heart Failure 2025
Heart Failure 2025 takes place from 17 to 20 May at the Sava Centar, Belgrade, Serbia and online. Explore the scientific programme
Free registration applies to accredited press.
Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles. Read the ESC media and embargo policy.
The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid.
The ESC Press Office decision is final regarding all press registration requests.
END
No cardiac safety concerns reported with a pharmaceutically manufactured cannabidiol formulation
2025-05-17
ELSE PRESS RELEASES FROM THIS DATE:
Scientists wash away mystery behind why foams are leakier than expected
2025-05-17
Tokyo, Japan – Researchers from Tokyo Metropolitan University have solved a long-standing mystery behind the drainage of liquid from foams. Standard physics models wildly overestimate the height of foams required for liquid to drain out the bottom. Through careful observation, the team found that the limits are set by the pressure required to rearrange bubbles, not simply push liquid through a static set of obstacles. Their approach highlights the importance of dynamics to understanding soft materials.
When you spray a foam on a wall, ...
TIFRH researchers uncover a mechanism enabling glasses to self-regulate their brittleness
2025-05-17
Materials with self-adaptive mechanical responses have long been sought after in material science. Using computer simulations, researchers at the Tata Institute of Fundamental Research (TIFR), Hyderabad, now show how such adaptive behavior can emerge in active glasses, which are widely used as models for biological tissues. The findings provide new insights—ranging from how cells might regulate their glassiness to aiding in the design of new metamaterials.
Glasses (or amorphous solids) are materials whose components ...
High energy proton accelerator on a table-top — enabled by university class lasers
2025-05-17
Laser Ion acceleration uses intense laser flashes to heat electrons of a solid to enormous temperatures and propel these charged particles to extreme speeds. These have recently gained traction for applications in selectively destroying cancerous tumor cells, in processing semiconductor materials, and due to their excellent properties - for imaging and fusion relevant conditions.
Massive laser systems with several Joules of light energy are needed to irradiate solids for the purpose. This produces a flash of ions which are accelerated to extreme speeds. Thus, emulating large million volt accelerators is possible ...
Life, death and mowing – study reveals Britain’s poetic obsession with the humble lawnmower
2025-05-16
University of Cambridge media release
Life, death and mowing – study reveals Britain’s poetic obsession with the humble lawnmower
UNDER STRICT EMBARGO UNTIL 00:01AM (UK TIME) ON SATURDAY 17TH MAY 2025
Over the last half-century, British poets including Philip Larkin and Andrew Motion have driven a ‘lawnmower poetry microgenre’, using the machine to explore childhood, masculinity, violence, addiction, mortality and much more, new research shows.
The study, published today in Critical Quarterly, argues that the tradition goes back to the 17th-century poet Andrew Marvell who used mowing – with a scythe – to comment ...
Ochsner Transplant Institute’s kidney program achieves ELITE Status
2025-05-16
NEW ORLEANS – Ochsner Health proudly shares its kidney transplant program, part of the Ochsner Transplant Institute, has been awarded ELITE Status within the credentialed Programs of Excellence transplant network by INTERLINK COE Networks & Programs. ELITE Status is awarded to only a select few programs nationwide certifying delivery of superior transplant care.
To earn this level of recognition, programs demonstrate superior results and exceptional performance based on a range of validated, risk-adjusted metrics. Programs with this designation achieve an INTERLINK Performance Model score statistically ...
Gender differences in primary care physician earnings and outcomes under Medicare Advantage value-based payment
2025-05-16
About The Study: In this cohort study, women primary care physicians in value-based payment models had equal or better quality outcomes and higher value-based earnings compared to men in their practice groups. These results substantiate prior evidence that women physicians perform better on process and outcome measures, yet receive incommensurate patient ratings. The reversal of the gender gap under value-based payment is likely due to fewer emergency department visits and hospitalizations among women primary care physicians’ patients and may in turn reflect better alignment of value-based models to practice patterns more ...
Can mindfulness combat anxiety?
2025-05-16
By Chris Woolston
If you’re anxious about work, finances, the state of the world, or anything else, you might try a moment of mindfulness. Paying close attention to the present moment without judgment — the basic idea behind all mindfulness techniques — can help calm anxiety and improve focus, said Resh Gupta, a postdoctoral research associate with the Mindfulness Science and Practice research cluster.
“A lot of research has shown that mindfulness can reduce anxiety symptoms,” she said.
The calming power of mindfulness is well-known to people ...
Could personality tests help make bipolar disorder treatment more precise?
2025-05-16
People with cancer, heart disease and other conditions have come to expect treatments that their medical teams “personalize” just for them, based on tests.
But care for mental health conditions hasn’t gotten to that point yet.
Now, a new study suggests that it might be possible to personalize care for people with bipolar disorder, using the results of detailed personality tests.
The research finds that such tests might help identify people who have certain combinations of personality traits ...
Largest genomic study of veterans with metastatic prostate cancer reveals critical insights for precision medicine
2025-05-16
TAMPA, Fla. (May 16, 2025) — In the largest clinical genomic profiling study of non-Hispanic Black men with metastatic prostate cancer to date, researchers from Moffitt Cancer Center, University of Pennsylvania, University of California Los Angeles and the Veterans Affairs (VA) National Precision Oncology Program found key differences in tumor biology between non-Hispanic Black and non-Hispanic white veterans, but similar survival outcomes when both groups had equal access to care.
The study, published in JAMA Network Open, analyzed data from more than 5,000 U.S. ...
UCF’s ‘bridge doctor’ combines imaging, neural network to efficiently evaluate concrete bridges’ safety
2025-05-16
Necati Catbas doesn’t hold a medical degree, but the UCF engineering professor is more than qualified to diagnose the health of bridges using a combination of emerging technologies.
Catbas collaborated with his former civil engineering student Marwan Debees ’23PhD, who now works as a NASA Bridge Program manager, on newly published research that details how infrared thermography, high-definition imaging and neural network analysis can combine to make concrete bridge inspections more efficient.
Catbas and Debees are hopeful that their findings, recently published in the Transportation Research Record, can be leveraged by engineers ...